States try to control medicaid pharmaceutical costs: numerous, diverse cost pressures force myriad reform efforts.

State Medicaid programs and the managed care plans that insure most recipients are struggling with the costs of hepatitis C medications and other specialty drugs that may be only the leading edge of a wave of expensive treatments for common conditions.